AXIM® Biotechnologies Nutraceutical Division Announces Cannabinoid-Based Wellness Gum Product Line at Benzinga Cannabis Capital Conference
(AXIM Biotech, AXIM or the Company) (OTCQB: AXIM), a world leader in cannabinoid research and development, announced today that its nutraceutical division, AXIM Wellness, has launched its flagship nutraceutical product line, AXIM Wellness Gum (Wellness Gum), at the Benzinga Cannabis Capital Conference in Chicago, IL.
- (AXIM Biotech, AXIM or the Company) (OTCQB: AXIM), a world leader in cannabinoid research and development, announced today that its nutraceutical division, AXIM Wellness, has launched its flagship nutraceutical product line, AXIM Wellness Gum (Wellness Gum), at the Benzinga Cannabis Capital Conference in Chicago, IL.
- Wellness Gum PM formulated with 5 mg of CBD, 25 mg of full-spectrum hemp oil, melatonin, L-Tryptophan and vitamin B3.
- We are excited for the launch of the Wellness Gum product line during the Benzinga Cannabis Capital Conference and look forward to discussing our new cannabinoid-based nutraceutical gum line with the cannabis community, said John W. Huemoeller II, Chief Executive Officer of AXIM Biotech.
- AXIM also intends to continue expanding the reach of its Wellness Gum line across the nation through individual sales representatives.